FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma By Ogkologos - January 10, 2025 897 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL July 29, 2021 Celebrating 75 years of NHS cancer care July 5, 2023 Catch up on Behind the Science 2021 – From funding stream... May 17, 2021 EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... December 17, 2021 Load more HOT NEWS Pursuing precision medicine in a flagship lung cancer trial 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable... ESMO Targeted Anticancer Therapies Congress 2023
